{
    "ticker": "VKI",
    "name": "Viking Therapeutics, Inc.",
    "description": "Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, Viking aims to address significant unmet medical needs by leveraging its expertise in metabolic and endocrine diseases. The company\u2019s lead product candidates, VK2809 and VK0214, are being developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and other related conditions. VK2809 is a selective thyroid hormone receptor beta agonist designed to reduce liver fat and improve metabolic health, while VK0214 targets rare genetic disorders associated with severe obesity. Viking Therapeutics is committed to advancing its pipeline through rigorous clinical trials and research, aiming to bring innovative treatments to market that can improve patient outcomes. The company continues to explore additional indications for its compounds and is dedicated to fostering partnerships that enhance its drug development efforts. With a strong scientific foundation and a dedicated leadership team, Viking Therapeutics is poised to make significant contributions to the field of metabolic health.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2012",
    "website": "https://www.vikingtherapeutics.com",
    "ceo": "Brian L. Turner",
    "social_media": {
        "twitter": "https://twitter.com/VikingThera",
        "linkedin": "https://www.linkedin.com/company/viking-therapeutics/"
    },
    "investor_relations": "https://www.vikingtherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Brian L. Turner",
            "position": "CEO"
        },
        {
            "name": "James E. O'Leary",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "VK2809",
                "VK0214"
            ]
        }
    ],
    "seo": {
        "meta_title": "Viking Therapeutics, Inc. | Innovative Therapies for Metabolic Disorders",
        "meta_description": "Viking Therapeutics, Inc. focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214.",
        "keywords": [
            "Viking Therapeutics",
            "Biotechnology",
            "Metabolic Disorders",
            "Pharmaceuticals",
            "VK2809",
            "VK0214"
        ]
    },
    "faq": [
        {
            "question": "What does Viking Therapeutics focus on?",
            "answer": "Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders."
        },
        {
            "question": "Who is the CEO of Viking Therapeutics?",
            "answer": "Brian L. Turner is the CEO of Viking Therapeutics, Inc."
        },
        {
            "question": "When was Viking Therapeutics founded?",
            "answer": "Viking Therapeutics was founded in 2012."
        },
        {
            "question": "What are Viking's lead product candidates?",
            "answer": "Viking's lead product candidates are VK2809 and VK0214."
        },
        {
            "question": "Where is Viking Therapeutics headquartered?",
            "answer": "Viking Therapeutics is headquartered in San Diego, California, USA."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "MRNA",
        "PFE",
        "BMY",
        "JNJ"
    ]
}